» Articles » PMID: 38092960

RUNX1-IT1 Acts As a Scaffold of STAT1 and NuRD Complex to Promote ROS-mediated NF-κB Activation and Ovarian Cancer Progression

Overview
Journal Oncogene
Date 2023 Dec 13
PMID 38092960
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulated expression of long-stranded non-coding RNAs is strongly associated with carcinogenesis. However, the precise mechanisms underlying their involvement in ovarian cancer pathogenesis remain poorly defined. Here, we found that lncRNA RUNX1-IT1 plays a crucial role in the progression of ovarian cancer. Patients with high RUNX1-IT1 expression had shorter survival and poorer outcomes. Notably, knockdown of RUNX1-IT1 suppressed the proliferation, migration and invasion of ovarian cancer cells in vitro, and reduced the formation of peritoneum metastasis in vivo. Mechanistically, RUNX1-IT1 bound to HDAC1, the core component of the NuRD complex, and STAT1, acting as a molecular scaffold of the STAT1 and NuRD complex to regulate intracellular reactive oxygen homeostasis by altering the histone modification status of downstream targets including GPX1. Consequently, RUNX1-IT1 activated NF-κB signaling and altered the biology of ovarian cancer cells. In conclusion, our findings demonstrate that RUNX1-IT1 promotes ovarian malignancy and suggest that targeting RUNX1-IT1 represents a promising therapeutic strategy for ovarian cancer treatment.

Citing Articles

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.


Redox-Regulated Iron Metabolism and Ferroptosis in Ovarian Cancer: Molecular Insights and Therapeutic Opportunities.

Liu D, Hu Z, Lu J, Yi C Antioxidants (Basel). 2024; 13(7).

PMID: 39061859 PMC: 11274267. DOI: 10.3390/antiox13070791.


Interplay between JAK/STAT pathway and non-coding RNAs in different cancers.

Farooqi A, Shepetov A, Rakhmetova V, Ruslan Z, Almabayeva A, Saussakova S Noncoding RNA Res. 2024; 9(4):1009-1022.

PMID: 39022684 PMC: 11254501. DOI: 10.1016/j.ncrna.2024.04.001.


GNL3L exhibits pro-tumor activities via NF-κB pathway as a poor prognostic factor in acute myeloid leukemia.

Li J, Wu Z, Pan Y, Chen Y, Chu J, Cong Y J Cancer. 2024; 15(13):4072-4080.

PMID: 38947394 PMC: 11212074. DOI: 10.7150/jca.95339.


The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications.

Hu Z, Yuan L, Yang X, Yi C, Lu J Front Oncol. 2024; 14:1332528.

PMID: 38725621 PMC: 11079149. DOI: 10.3389/fonc.2024.1332528.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Peres L, Cushing-Haugen K, Kobel M, Harris H, Berchuck A, Rossing M . Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst. 2018; 111(1):60-68. PMC: 6335112. DOI: 10.1093/jnci/djy071. View

3.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

4.
Rosendahl M, Hogdall C, Mosgaard B . Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Int J Gynecol Cancer. 2016; 26(4):680-7. DOI: 10.1097/IGC.0000000000000675. View

5.
Goodall G, Wickramasinghe V . RNA in cancer. Nat Rev Cancer. 2020; 21(1):22-36. DOI: 10.1038/s41568-020-00306-0. View